immobilized for more than 72 h without any DVT prophylaxis. Conspicuous by its absence is any report of such devices precipitating an embolic event during general surgery. We cannot establish causality. It is possible that the embolism would have occurred irrespective of the placement of the sequential devices because of the presence of multiple risk factors in our patient, including age, obesity, malignancy, estrogen replacement hormones, and relative immobility (because of illness). Nevertheless, the temporal association between activation of the pneumatic device and sudden onset of symptoms at least suggests that the application of preventive measure may have paradoxically triggered a life-threatening complication.

Such an anecdotal report should not be held up as the sole basis for changing clinical practice, particularly when benefits of these compression devices outweigh the risk of complication. However, we suggest that these well-intentioned prophylactic measures may have adverse consequences, particularly if they are not used appropriately. Clinicians who care for patients with moderate to high risk for DVT who are fitted with these devices should remain alert for signs and symptoms of acute embolism, especially during the first few minutes and hours after their application.

References


Reversal of Intraoperative Myocardial Ischemia with a Hemoglobin-based Oxygen Carrier

Marc Niquille, M.D.,* Marc Touzet, M.D.,† Isabelle Leblanc, M.D.,‡ Jean-François Baron, M.D.§

THE hemoglobin-based oxygen-carrying solutions currently under investigation have oxygen transport and exchange properties similar to blood. However, their cardiovascular effects are still a subject of controversy. In particular, there have been several reports of extensive vasoconstriction,1–4 and several authors have suggested that this effect may be deleterious for the myocardium in patients with coronary artery disease.5–6

Case Report

A 64-yr-old man with abdominal aortic occlusive disease was admitted for an occlusion of the right lower limb of an aortobifemoral graft. The patient had previously undergone several radiologic and surgical lower-limb revascularization procedures. The patient reported an uncomplicated myocardial infarction after a previous aortobifemoral grafting procedure. However, there was no subsequent angina or cardiac insufficiency. On admission, his electrocardiogram showed a atrial fibrillation longstanding with a ventricular rate of 90 beats/min. Intravenous heparin was started but was complicated by a significant lower gastrointestinal hemorrhage leading to a decrease in hemoglobin...
Before surgery, the patient was enrolled in a randomized, single-blind, erythrocyte-controlled trial to evaluate the efficacy and the safety of an hemoglobin-based oxygen carrier (HBOC-201). The patient was informed of all risks and potential benefits, and written informed consent was obtained. The patient was not enrolled in a predonation program and was not treated with erythropoietin.

Anesthesia was induced using titrated doses of fentanyl, propofol, and atracurium. A pulmonary artery catheter was inserted, revealing high pulmonary capillary wedge pressure (25 mmHg). Anesthesia was maintained using a continuous infusion of propofol and intermittent fentanyl. Surgery was uneventful until aortic cross-clamping. During cross-clamping, the patient developed progressive systolic and diastolic hypotension to 80/50 mmHg (fig. 1) associated with new 2-mm ST-T segment depression on monitored standard leads II and V5. Pulmonary capillary wedge pressure remained at 25 mmHg. A dobutamine (6 μg·kg⁻¹·min⁻¹) and nitroglycerin (0.5 μg·kg⁻¹·min⁻¹) infusion was started. Blood pressure and heart rate increased (fig. 1) but with no improvement in ST-segment depression. Hemoglobin concentration at this point was 7.6 g/dl, and the decision to transfuse blood was made. In accordance with the trial protocol, the patient was randomly assigned to receive 60 g (500 ml) of HBOC-201. After the start of the infusion, systemic arterial blood pressure slightly increased and heart rate decreased with rapid normalization of the ST-T segment (fig. 1). Dobutamine and nitroglycerin infusions were stopped, and surgery was completed. During the postoperative period, recurrent tachycardia and ST-T changes were successfully treated by a second infusion of 30 g HBOC-201. On postoperative day 1, total hemoglobin was 11.3 g/dl with a plasma-free hemoglobin level of 2.2 g/dl. Tropinin Ic levels remained normal, and the patient was discharged to the ward. On postoperative day 6, a new episode of gastrointestinal hemorrhage was observed. Total hemoglobin decreased from 9.0 to 7.4 g/dl, and 60 g HBOC-201 was infused without adverse events. Reexploration of the gastrointestinal tract revealed four small benign rectal polyps that were removed.

On postoperative day 2, moderate jaundice with a transient increase in AST (493 UI/l; normal values = 15–48 UI/l), ALT (121 UI/l; normal values = 10–40 UI/l), and lipase (120 UI/l; normal values = 7–60 UI/l) was noted. These returned to baseline within 3 days, without clinical or ultrasound evidence of hepatic or pancreatic lesion. The patient was discharged home on postoperative day 28 with a hematocrit of 37% and total hemoglobin of 11.6 g/dl without receiving allogenic packed erythrocytes or erythropoietin therapy.

Discussion

Hemoglobin-based oxygen carrier 201 is an intravenous solution of glutaraldehyde-polymerized bovine hemoglobin. Cardiovascular effects of HBOC-201 are still a subject of controversy because it has been demonstrated that iso-volumic exchange during acute normovolemic hemodilution may result in decreased cardiac output associated with peripheral vasoconstriction.3,4 Several investigators have stressed that this effect may be deleterious, especially in patients with coronary artery disease.5,6

This high-risk patient with cardiac and vascular disease experienced intraoperative myocardial ischemia likely related to anemia, hypotension, and tachycardia. The infusion of HBOC-201 led to a rapid hemodynamic improvement with normalization of ST-T segment abnormalities. This beneficial effect may have been related either to the cardiovascular effects of HBOC-201 or to its ability to improve tissue oxygenation.

Hemoglobin-induced vasoconstriction may result in reduced blood flow to vital organs and severe pulmonary hypertension.7 It has been suggested that this vasoconstrictive effect may be mediated in part by endothelin, inhibition of nitric oxide, and sensitization of peripheral α receptors.8 The magnitude of this vasoconstrictive effect seems to be attenuated by polymerization of hemoglobin either by glutaraldehyde9 as HBOC-201 or α-raffinose.10 The effect of polymerization is likely caused by surface modification
and/or intramolecular cross-linking, rather than an increase in molecular size limiting extravasation. The consequences of the vasoconstrictive effect of HBOC on coronary circulation is also unclear. Early studies performed with incompletely purified hemoglobin solutions described coronary vasoconstriction. More recent studies have used modified, highly purified, and heat pasteurized hemoglobin-based solutions (diaspirin cross-linked). Infusion of diaspirin cross-linked hemoglobin increases blood pressure as well as blood flow to the myocardium and gastrointestinal tract. An endothelin receptor antagonist (phosphoramidon) could attenuate the systemic hemodynamic effects and some regional circulatory effects of diaspirin cross-linked hemoglobin. However, the increase in blood flow to the myocardium could not be modified by an endothelin receptor antagonist. Accordingly, in our case report, it may be suggested that cardiovascular effects of HBOC-201 may have contributed to the improvement in the hemodynamic status of the patient by increasing arterial pressure, coronary perfusion pressure, and decreasing heart rate. However, we cannot rule out the possibility that the same effects could have been accomplished with another colloid.

In addition, when compared with blood, HBOCs could improve tissue oxygenation more significantly. Standl et al. compared the effects of stored erythrocytes, freshly donated blood, and HBOC-201 on muscular tissue oxygenation after extreme isovolemic hemodilution in a canine model. At a hematocrit of 10%, skeletal muscle tissue oxygen tension was decreased by approximately 50%. After transfusion, an increase of 0.7 g/dl of hemoglobin using HBOC-201 resulted in restoration of baseline tissue oxygenation. An increase in hemoglobin of 2.7 and 2.1 g/dl with fresh and stored blood, respectively, were needed to restore normal tissue oxygenation. These results demonstrate a higher oxygenation potential of HBOC as compared with fresh or stored erythrocytes, in relation with better oxygen extraction.

The right shift of the oxygen–hemoglobin dissociation curve (P50 32–35 mmHg) and a better distribution of blood oxygen-carrying capacity at the microcirculatory level are the main mechanisms explaining the improvement of tissue oxygenation. Whether this played a role in the event observed in our patient is unknown. The jaundice is explained by the intracellular diffusion and catabolism of the free hemoglobin.

References

7. de Figueiredo LF: Vasoactive properties of synthetic blood substitutes. Medicina 1998; 58:403–10
Acute Myocardial Ischemia after Administration of Ondansetron Hydrochloride

Voytek Bosek, M.D.*, Pink Hu, M.D.,† Lary A. Robinson, M.D.‡

ONDANSETRON hydrochloride (Zofran; Glaxo Wellcome Inc., Research Triangle Park, NC) antagonizes the effect of serotonin at the 5-hydroxytryptamine3 (5-HT3) receptors.1 Serotonin is released from the enterochromaffin cells of the small intestine, stimulates the vagal afferents through the 5-HT3 receptors, and initiates the vomiting reflex. Through its 5-HT3-blocking effect, ondansetron hydrochloride has been progressively introduced into the practice of anesthesiology to treat perioperative nausea and vomiting. Administration of ondansetron is believed to be safe and is associated with very few reported serious side effects.1,2 However, we describe a patient with no history of cardiac abnormalities who experienced a severe episode of acute myocardial ischemia that occurred during the intravenous injection of ondansetron in the early postoperative period.

Key words: Antiemetics; perioperative complications; serotonin antagonists; ventricular tachycardia.

Case Report

A 60-yr-old woman who was a nonsmoker developed slight exertional wheezing. A 2-cm-diameter left lower lobe lung mass with a surrounding infiltrate was found on a chest radiograph and subsequent computed chest tomography, with no lymphadenopathy. A transbronchial biopsy provided the diagnosis of well-differentiated adenocarcinoma with bronchioloalveolar features. She had a medical history of several prior minor operations with no complications. She also reported the subjective feeling of an occasional extrasystole, but no other cardiac symptoms were elicited. She was very physically active, exercising frequently each week in a health club. Her physical examination was entirely normal. The preoperative electrocardiogram (ECG) demonstrated only minimal nonspecific S-T changes. Other than a mild anemia (hemoglobin, 11.5 g/dl), results of her laboratory tests were normal. Pulmonary function testing showed very mild airway obstruction.

The patient (52 kg, 162 cm, American Society of Anesthesiologists physical status II) was scheduled for a left lower lobectomy. On the morning of surgery, a thoracic epidural catheter was placed with no paresthesias, blood, or cerebrospinal fluid return. The patient then underwent an uncomplicated left lower lobectomy and mediastinal lymphadenectomy with general anesthesia; ventilatory separation of the lungs was accomplished with a left-sided double-lumen endotracheal tube. She was easily extubated in the operating room. The initial postoperative course was uneventful. The patient received good pain relief from epidurally administered ropivacaine and fentanyl. The final pathology revealed a 2.1 × 2.0-cm well-differentiated bronchioloalveolar carcinoma involving the visceral pleura, with all lymph nodes free of metastases, staged as T2N0M0 (stage IB).

In the surgical intensive care unit on the first postoperative day while still on continuous ECG monitoring (fig. 1), the patient started to complain of nausea, worse than the mild intermittent nausea present on the day of surgery. She received droperidol 0.625 mg intravenously in three consecutive doses approximately 30 min apart, but without adequate therapeutic effect. Her continuously monitored arterial oxygen saturation on room air at that time was 99%. Because of the continuing nausea, antiemetic ondansetron was prescribed. Immediately after intravenous administration of 2.0 mg ondansetron, the

Anesthesiology, V 92, No 3, Mar 2000